Compare Royal Caribbean Cruises Ltd (RCL) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs 10X Genomics Inc — how do they compare? Royal Caribbean Cruises Ltd trades at $286 (market cap $76.75B), while 10X Genomics Inc trades at $46.82 (market cap $5.48B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 14× 10X Genomics Inc's market cap, and Royal Caribbean Cruises Ltd pays a 1.75% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| RCL | TXG | |
|---|---|---|
Market Cap | $76.75B | $5.48B |
Sector | Consumer Cyclical | Health |
52-Week High | $365.84 | $47.20 |
52-Week Low | $246.71 | $11.34 |
Enterprise Value | $98.03B | $5.02B |
Dividend Yield | 1.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $287.90, near its 52-week high, with a modest 0.33% daily gain. The stock shows strong fundamental momentum, with revenue growing from $8.8B in 2022 to $17.9B in 2025 and net income surging to $4.3B. However, technical indicators signal a bearish trend, with moving averages and oscillators pointing to near-term pressure. Recent news highlights earnings anticipation and board appointments, while analyst consensus remains bullish with a $328 price target.
The outlook for RCL is positive based on robust earnings growth and expanding profit margins, but risks include high debt levels and potential economic sensitivity. Investor sentiment is mixed, with technical weakness offset by strong fundamentals. The stock presents a long-term opportunity if it can maintain operational execution amid competitive and macroeconomic challenges.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
